OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2004 Individual Investigator Grant Recipient – Anda Vlad

Anda Vlad, M.D., Ph.D.
University of Pittsburgh
Immunotherapy of Ovarian Cancer Using Certain Tumor Specific Glycopeptides

Project Summary

To have an effective cancer vaccine, it is important to identify molecules on tumor cells that the human immune system can see as foreign (tumor antigens). Once found, these tumor antigens can then be used in vaccine preparations to induce a strong immune response that will specifically destroy tumor cells that express this molecule and not normal cells. Dr. Vlad has developed an ovarian cancer vaccine based on the MUC1 tumor antigen, which is expressed at low levels in normal epithelial cells and overexpressed in ovarian cancer. The chemical backbone of MUC1is identical in normal and tumor MUC1, but the cancer form carries tumor-specific carbohydrates. Dr. Vlad proposes to test a vaccine based on the tumor-like, glycosylated MUC1, called Tn100mer. The vaccine delivers small pieces of the tumor form of MUC1 to specialized immune cells, called dendritic cells, which will then activate other cells of the immune system (like T and B cells) to seek out and destroy MUC1-expressing cancer cells. Results from the study of tumor-specific immunotherapy through vaccination with the MUC1 tumor antigen, especially in the context of minimal residual disease following removal of the tumor, could potentially be crucial for prevention of recurrences.